J&J to Buy Intra-Cellular for About $14 Billion

Estimated read time 1 min read


Johnson & Johnson agreed to acquire Intra-Cellular Therapies, a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on “Bloomberg Open Interest.”

Source link

You May Also Like

More From Author

+ There are no comments

Add yours